

Prescriber Criteria Form

Emgality 2026 PA Fax 3111-A v2 010126.docx

Emgality (galcanezumab-gnlm)

Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Emgality (galcanezumab-gnlm).

Drug Name:
Emgality (galcanezumab-gnlm)

Patient Name:

Patient ID:

Patient DOB:

Patient Phone:

Prescriber Name:

Prescriber Address:

City:

State:

Zip:

Prescriber Phone:

Prescriber Fax:

Diagnosis:

ICD Code(s):

Please circle the appropriate answer for each question.

1	Is the requested drug being prescribed for the preventive treatment of migraine? [If no, then skip to question 5.]	Yes	No
2	Will the requested drug be used concurrently with another calcitonin gene-related peptide (CGRP) receptor antagonist? [If yes, then no further question.]	Yes	No
3	Has the patient received at least 3 months of treatment with the requested drug? [If no, then no further questions.]	Yes	No
4	Has the patient had a reduction in migraine days per month from baseline? [No further questions.]	Yes	No
5	Is the requested drug being prescribed for the treatment of episodic cluster headaches? [If no, then no further questions.]	Yes	No
6	Has the patient received at least 3 weeks of treatment with the requested drug? [If no, then skip to question 8.]	Yes	No
7	Has the patient had a reduction in weekly cluster headache attack frequency from baseline? [No further questions.]	Yes	No

8	Has the patient experienced an inadequate treatment response, intolerance, or does the patient have a contraindication to a triptan 5-HT1 receptor agonist?	Yes	No
---	---	-----	----

Comments:	
-----------	--

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

Prescriber (or Authorized) Signature: _____	Date: _____
---	-------------